Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - Relationship with bone mineral density, disease activity and bone turnover

Clinical Rheumatology

Volumn 26, Issue 12, 2007, Pages 2127-2135

  Oelzner, Peter ^a   Franke, S ^a   Lehmann, G ^a   Eidner, T ^a   Muller A ^a   Wolf, G ^a   Hein, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bone mineral density; Osteoprotegerin; RANKL; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; CYTOKINE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; GLYCOPROTEIN GP 130; INTERLEUKIN 6; LIGAND; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PYRIDINOLINE;

ADULT; AGE; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR NECK; GENDER; HUMAN; LINEAR REGRESSION ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; SEVERITY OF ILLNESS INDEX;

EID: 36249012519     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0639-5     Document Type: Article

References (52)

1. Gough A, Sambrook P, Devlin J, Huisson A, Njeh C, Robbins S, Nguyen T, Emery P (1998) Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282-1289
2. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NfkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30:340-346
3. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23-27
4. Henderson NK, Sambrook PN (1996) Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr Opin Rheumatol 8:365-369
5. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, Lovell DJ (1997) Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 40:1967-1975
6. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS (1996) Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 39:746-757
7. Laan RF, van Reil PL, van Earning LJ, Lemmens AM, Ruijs SH, van de Putte LB (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisolone therapy. Br J Rheumatol 31:91-96
8. Laan RF, van de Putte LB, van Reil PL, van Earning LJ, van't Hof MA, Lemmens AM (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 119:963-968
9. Hall GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510-1516
10. Kröger H, Honkanen R, Saarikoski S, Alhava E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis - a population based study. Ann Rheum Dis 53:18-23
11. Michel BA, Bloch DA, Fries JF (1991) Predictors of fractures in early rheumatoid arthritis. J Rheumatol 18:804-808
12. Sambrook PN, Eisman JA, Champion JD, Yeates MD, Pocock NA, Ebrl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721-728
13. Michel BA, Bloch DA, Wolfe F, Fries JF (1993) Fractures in rheumatoid arthritis: An evaluation of associated risk factors. J Rheumatol 20:1666-1669
14. Sambrook PN, Eisman JA, Champion JD, Pocock NA, Yeates MD, Ebrl S (1986) Osteoporosis in rheumatoid arthritis: Safety of low dose corticosteroids. Ann Rheum Dis 45:950-953
15. Oelzner P, Müller A, Deschner F, Hüller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193-198
16. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
17. Giuliani N, Sansoni P, Girasole G, Vescovini R, Passeri G, Passeri M, Pedrazzoni M (2001) Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol 36:547-557
18. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T (1985) Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28:25-31
19. Kroger H, Arnala I, Rehnberg V, Hamalainen M, Alhava E (1994) Histomorphometry of periarticular bone in rheumatoid arthritis. Ann Chir Gynaecol 83:56-62
20. Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono K (1994) Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 21:830-835
21. Toritsuka Y, Nakamura N, Lee SB, Hashimoto J, Yasui N, Shino K, Ochi T (1997) Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J Rheumatol 24:1690-1696
22. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
23. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K (1999) A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25:109-113
24. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250-258
25. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269
26. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
27. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Gortz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48:2042-2051
28. Saidenberg-Kermanach N, Corrado A, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal ME (2004) TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200-1207
29. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C (1998) Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159:191-195
30. Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
31. Müller A, Hein G, Franke S, Herrmann D, Henzgen S, Roth A, Stein G (1996) Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography. Rheumatol Int 16:23-28
32. Einspruch EL (ed) (2005) An introductory guide to SPSS for windows. Sage Publications, Thousand Oaks, CA, USA
33. Furumitsu Y, Inaba M, Yukioka K, Yukioka M, Kumeda Y, Azuma Y, Ohta T, Ochi T, Nishizawa Y, Morii H (2000) Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 27:64-70
34. Kaufmann J, Mueller A, Voigt A, Carl HD, Gursche A, Zacher J, Stein G, Hein G (2003) Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis. Rheumatology 42:314-320
35. Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F (2004) Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: Is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 31:986-991
36. Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A (2001) Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 30:229-234
37. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinki J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46:1744-1753
38. Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-{alpha} antibody: A prospective open-label pilot study. Rheumatology 44:1546-1548
39. Landewe RBM, Geusens P, Boers M, Garnero P, van der Heijde D, van der Linden S (2005) Serum-RANK-Ligand amplifies the effect of disease activity on radiographic progression. Ann Rheum Dis 62 (Suppl I):133
40. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259
41. Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248:454-457
42. Chen RA, Goodman WG (2004) Role of calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 286:1005-1011
43. Ebert R, Jovanovic M, Ulmer M, Schneider D, Meissner-Weigl J, Adamski J, Jakob F (2004) Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1 alpha-hydroxylase promoter. Mol Endocrinol 18:2440-2450
44. O'Brien EA, Williams JH, Marshall MJ (2001) Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach the endocranial membrane. Bone 28:208-214
45. Nagai M, Sato N (1999) Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 257:719-723
46. Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol 60:87-91
47. Bernstein CN, Sargent M, Leslie WD (2005) Serum osteoprotegerin is increased in Crohn's disease: A population-based case control study. Inflamm Bowel Dis 11:325-330
48. Fabrega E, Orive A, Garcia-Suarez C, Garcia-Unzueta M, Antonio Amado J, Pons-Romero F (2005) Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 25:305-310
49. Grigorie D, Neacsu E, Marinescu M, Popa O (2003) Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Rom J Intern Med 41:409-415
50. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jimenez F, Munoz-Torres M (2005) The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 16:1368-1374
51. Tourinho TF, Stein A, Castro JA, Brenol JC (2005) Rheumatoid arthritis: evidence for bone loss in premenopausal women. J Rheumatol 32:1020-1025
52. Barrera P, Boerbooms AM, Sauerwein RW, Demacker PN, van de Putte LB, van der Meer JW (1994) Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity. Lymphokine Cytokine Res 13:155-159